Robin Reschke: Extracorporeal photopheresis for managing immune checkpoint inhibitor-induced toxicities
Robin Reschke, Physician scientist at the University Hospital Heidelberg, shared a post on LinkedIn about a paper hw co-authored with colleagues published in Signal Transduction and Targeted Therapy:
“New research highlight!
We covered an exciting Cancer cell study by Robert Zeiser, Lukas Braun and et al. on extracorporeal photopheresis (ECP) as a novel way to manage immune-related adverse events (irAEs) caused by immune checkpoint inhibitors – without compromising anti-tumor effects!
ECP modulates the immune system by:
- Reducing harmful T cell and neutrophil activity
- Promoting anti-inflammatory M2 macrophages via adiponectin
- Preserving tumor-fighting T cells
In preclinical models and a phase 1b/2 trial, ECP showed impressive results
This could be a game changer for patients with steroid-refractory toxicities. No more compromising between efficacy and safety!
Check out the full highlight.”
Authors: Robin Reschke, Alexander Enk, Jessica Hassel.
More posts featuring Robin Reschke.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023